---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-117720"
form_type: "8-K"
ticker: "TLSI"
cik: "0001826667"
company_name: "TriSalus Life Sciences, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:57:36.622935+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TriSalus Q3 revenue $5.2M (+32% YoY); net loss $1.7M; PERIO-01 median PFS 11.7 months

## Summary
- Q3 revenue $5.2M, up 32% YoY; nine-month revenue $12.8M, up 39% YoY; gross margin 89%.
- Operating loss $18.5M (incl. $4.8M deSPAC costs); net loss $1.7M; diluted EPS loss $0.13.
- PERIO-01 Phase 1 data: median PFS 11.7 months, DCR 81%, 1-year OS 86%.
- PERIO-03 initial safety/feasibility for pancreatic cancer; dose expansion with anti-PD-1 expected early 2024.
- Appointed Jodi Devlin as President, Commercial Operations.

## SEC filing metadata
- accession: 0001104659-23-117720
- form_type: 8-K
- ticker: TLSI
- cik: 0001826667
- company_name: TriSalus Life Sciences, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826667/000110465923117720/0001104659-23-117720-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826667/000110465923117720/tm2330637d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-117720
- JSON: https://secwatch.observer/filing/0001104659-23-117720.json
- Plain text: https://secwatch.observer/filing/0001104659-23-117720.txt

## Key facts
- Earnings Releases
  TriSalus Life Sciences, Inc. reported the three and nine month periods ended September 30, 2023 results: revenue $5.2 million, net income $1.7 million and $27.0 million, respectively, for the third quarter and nine months ended September 30, 2023, EPS Basic and diluted loss per share for the three and nine months ended September 30, 2023, was $0.
  - Period: the three and nine month periods ended September 30, 2023
  - Revenue: $5.2 million
  - Net income: $1.7 million and $27.0 million, respectively, for the third quarter and nine months ended September 30, 2023
  - EPS: Basic and diluted loss per share for the three and nine months ended September 30, 2023, was $0
  - Result: reported results
  source text: Financial Results and Provides Business Update Completed merger with MedTech Acquisition Corporation (MTAC) and started public trading August 11 th Reported 3Q23 revenues of $5.2 million in 3Q23, up 32% over prior year and nine-month year to date net revenues of $12.8 million, up 39% over prior year Favorable Phase 1 uveal melanoma PERIO-01 data demonstrating
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826667/000110465923117720/0001104659-23-117720-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.